The EU Just Pulled a Nasty Stunt That Has Trump’s Trade Team Fuming
Europe's socialist bureaucrats have been living off American innovation for decades.
Now they're making a move that threatens the entire pharmaceutical industry.
And the EU just pulled a nasty stunt that has Trump's trade team fuming.
Brussels bureaucrats quietly target American pharmaceutical patents
The European Union is quietly pushing through regulatory changes that would gut American pharmaceutical patent protections while Americans are still paying three times what Europeans pay for the same drugs.
The proposed reforms expand something called the "Bolar exemption" — which allows generic drug makers to prepare to commercialize medicines while American patents remain in effect.¹
Translation: European, Chinese, and Indian companies can get ready to steal American innovations before the patents even expire.
Former Rep. Brad Wenstrup (R-OH) exposed the scheme in a blistering op-ed that has MAGA leaders demanding action.
"These changes would undermine international obligations to respect patents and enable European, Chinese, and Indian companies to prepare and seek to commercialize generic versions of medicines while American patents remain in effect," Wenstrup wrote.²
American pharmaceutical companies spend over $2 billion bringing a single new drug to market.
The United States accounts for 78% of all global drug profits — profits that drive the innovation saving lives worldwide.³
Europeans get access to these breakthrough medications at deeply discounted prices while Americans shoulder the entire burden at pharmacy counters.
Now Brussels wants to make the problem worse by letting foreign companies prepare generic knockoffs before American patents expire.
The EU already has a $250 billion trade deficit with the United States.⁴
American consumers spend roughly three times as much on prescription drugs as consumers in France, Germany, Italy, Spain, and the United Kingdom.⁵
Europe drives hard bargains through their state-run health systems — they can impose price caps or refuse to allow drugs onto national formularies.
Medicare was expressly forbidden from similar bargaining when the drug benefit was added during the Bush Administration.
So Americans subsidize research to treat diabetes, heart disease, and dementia while Europeans freeload.
Trump Administration already forcing change on pharmaceutical pricing
The outrage spread like wildfire across social media once Wenstrup's piece hit.
Alex Bruesewitz, adviser to President Trump, called the EU proposal "pretty shocking given that Europe wants us to fund all of their national defense."⁶
"They are trying to push through a regulatory change that would allow them to take advantage of our patented innovations," Bruesewitz wrote. "That's unacceptable."
X user Wall Street Mav laid out exactly how the scam works.
"Europe gets vastly cheaper drug prices, with Americans paying 3x more for name-brand drugs that are still under patent protection," he explained. "The EU just allows their companies to make cheap generics, forcing Americans to carry the R&D costs and pay for it all."⁷
"Once again, the socialists in the EU expect the USA to pay for everything while they get a free ride," he added. "Using the hammer of tariffs, President Trump is forcing changes in US-EU trade talks."
President Trump has already secured a groundbreaking agreement with the United Kingdom where they agreed to increase what they pay for new medicines by 25%.⁸
The UK also agreed to ensure higher prices for new medicines aren't eroded by portfolio-wide concessions or rebate schemes.
In exchange, the Trump Administration exempted UK pharmaceuticals from Section 232 tariffs and agreed not to target UK pricing practices in any Section 301 investigation.
Trump is the first American President to force trading partners to pay their fair share for pharmaceutical innovation.
But the EU's patent grab shows Brussels hasn't gotten the message yet.
The Trump Administration has launched Section 232 investigations into pharmaceutical imports and is preparing Section 301 trade probes into foreign drug pricing practices.⁹
Commerce Secretary Howard Lutnick made clear these investigations could result in tariffs to protect American innovation and manufacturing.
X user Declaration of Memes captured conservative fury over Europe's latest betrayal.
"Why is Europe constantly undermining America?" he wrote. "We basically defend and protect them at a HUGE cost to American taxpayers. Do we get thanked? No, instead we get constantly undermined."¹⁰
"When it comes to patents, predominantly intellectual property and pharmaceutical patents, the EU continues to take advantage of America," he continued. "So does America need to launch a Section 301 investigation to get to the bottom of this and what these socialist bureaucrats are doing in Brussels?"
President Trump has repeatedly said it's time to end the unfair practice where Americans subsidize drug development for the entire world.
The EU's attempted patent grab proves he's exactly right.
¹ Brad Wenstrup, "Europe Quietly Plans to Freeload Off American Innovation," Townhall, December 2025.
² Ibid.
³ Dana Goldman and Darius Lakdawalla, "This Is What's at Stake if U.S. Drug Prices Fall — and Europeans Don't Pay More," USC Schaeffer Center, February 1, 2018.
⁴ Alex Bruesewitz, X post, December 9, 2025.
⁵ Goldman and Lakdawalla, USC Schaeffer Center.
⁶ Bruesewitz, X post.
⁷ Wall Street Mav, X post, December 9, 2025.
⁸ "U.S. Government Announces Agreement in Principle with the United Kingdom on Pharmaceutical Pricing," United States Trade Representative, December 2025.
⁹ "Trump Admin Readies 'Imminent' Probe Into Other Nations' Drug Pricing," Fierce Pharma, October 22, 2025.
¹⁰ Declaration of Memes, X post, December 9, 2025.
